Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia
Open Access
- 26 August 2022
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 25 (8) , e25989
Abstract
Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiretroviral therapy (ART) for HIV treatment programme in Asia. We assessed the association between routine VL testing and virological failure (VF) and determine factors associated with switching to second‐line regimen.Methods: Among 21 sites from the TREAT Asia HIV Observational Database (TAHOD), people living with HIV (PLHIV) aged ≥18 years initiating ART from 2003 to 2021 were included. We calculated the average number of VL tests per patient per year between the date of ART initiation and the most recent visit. If the median average number of VL tests was ≥ 0.80 per patient per year, the site was classified as a routine VL site. A site with a median < 0.80 was classified into the non‐routine VL sites. VF was defined as VL ≥1000 copies/ml during first‐line therapy. Factors associated with VF were analysed using generalized estimating equations with Poisson distribution.Results: Of 6277 PLHIV starting ART after 2003, 3030 (48%) were from 11 routine VL testing sites and 3247 (52%) were from 10 non‐routine VL testing sites. The median follow‐up was 9 years (IQR 5–13). The median age was 35 (30–42) years; 68% were male and 5729 (91%) started non‐nucleoside reverse‐transcriptase inhibitor‐based regimen. The median pre‐ART CD4 count in PLHIV from routine VL sites was lower compared to non‐routine VL sites (144 vs. 156 cells/mm3, p 3. A total of 817 (13%) patients switched to second‐line regimen at a rate of 1.44 (95% CI 1.35–1.54) per 100 PY. PLHIV at routine VL monitoring sites were at higher risk of switching than those at non‐routine VL sites (adjusted sub‐hazard ratio 1.78 95% CI [1.17–2.71]).Conclusions: PLHIV from non‐routine VL sites had a higher incidence of persistent VF and a low switching regimen rate, reflecting possible under‐utilized VL testing.Keywords
This publication has 26 references indexed in Scilit:
- HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the IeDEA CollaborationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, UgandaBMC Infectious Diseases, 2017
- Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoringThe Lancet Infectious Diseases, 2017
- A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database CohortAIDS Research and Human Retroviruses, 2016
- Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges: Table 1.Clinical Infectious Diseases, 2016
- No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care ProjectBMC Public Health, 2015
- Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysisThe Lancet HIV, 2015
- Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in ThailandPLOS Medicine, 2013
- The TREAT Asia HIV Observational DatabaseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999